
Company valuation, historical trends, and peer comparisons.
According to Replimune Group, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.54B. This represents a change of 67.41% compared to the average of 918.19M of the last 4 quarters.
The mean historical Enterprise Value of Replimune Group, Inc. over the last ten years is 631.62M. The current 1.54B Enterprise Value has changed 143.36% with respect to the historical average. Over the past ten years (40 quarters), REPL's Enterprise Value was at its highest in in the June 2021 quarter at 1.83B. The Enterprise Value was at its lowest in in the September 2017 quarter at 0.
Average
631.62M
Median
564.25M
Minimum
305.45M
Maximum
1.26B
Discovering the peaks and valleys of Replimune Group, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 289.60%
Maximum Annual Enterprise Value = 1.26B
Minimum Annual Increase = -45.24%
Minimum Annual Enterprise Value = 305.45M
| Year | Enterprise Value | Change |
|---|---|---|
| 2026 | 612.51M | -18.39% |
| 2025 | 750.54M | 45.46% |
| 2024 | 516.00M | -45.24% |
| 2023 | 942.21M | 15.83% |
| 2022 | 813.46M | -35.53% |
| 2021 | 1.26B | 289.60% |
| 2020 | 323.88M | -4.86% |
| 2019 | 340.43M | -24.34% |
| 2018 | 449.93M | 47.30% |
The current Enterprise Value of Replimune Group, Inc. (REPL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
626.35M
5-year avg
726.94M
10-year avg
631.62M
Replimune Group, Inc.’s Enterprise Value is greater than Janux Therapeutics, Inc. (1.08B), less than Iovance Biotherapeutics, Inc. (3.42B), less than ImmunityBio, Inc. (9.32B), greater than Agenus Inc. (319.59M), greater than MacroGenics, Inc. (74.09M), greater than CytomX Therapeutics, Inc. (470.63M), greater than Adagene Inc. (-34854471.00), greater than Compugen Ltd. (178.88M), less than Nurix Therapeutics, Inc. (2.17B), greater than Lyell Immunopharma, Inc. (230.81M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 1.08B | $1.08B | |
| 3.42B | $3.49B | |
| 9.32B | $8.58B | |
| 319.59M | $297.62M | |
| 74.09M | $152.91M | |
| 470.63M | $482.15M | |
| -34854471.00 | $86.97M | |
| 178.88M | $186.13M | |
| 2.17B | $2.82B | |
| 230.81M | $266.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Replimune Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Replimune Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Replimune Group, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Replimune Group, Inc. (REPL)?
What is the 3-year average Enterprise Value for Replimune Group, Inc. (REPL)?
What is the 5-year average Enterprise Value for Replimune Group, Inc. (REPL)?
How does the current Enterprise Value for Replimune Group, Inc. (REPL) compare to its historical average?